[1]崔斐,罗荣城,陈锦章,等.紫杉醇联合Herceptin或表阿霉素治疗Her-2/neu阳性乳腺癌患者的临床疗效[J].南方医科大学学报,2005,(12):1533-1536.
 CUI Fei,LUO Rong-cheng,CHEN Jin-zhang,et al.Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu[J].Journal of Southern Medical University,2005,(12):1533-1536.
点击复制

紫杉醇联合Herceptin或表阿霉素治疗Her-2/neu阳性乳腺癌患者的临床疗效()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2005年12期
页码:
1533-1536
栏目:
出版日期:
2005-12-01

文章信息/Info

Title:
Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu
作者:
崔斐 罗荣城 陈锦章 陈斌 黄宇贤
南方医科大学南方医院肿瘤中心, 广东, 广州, 510515
Author(s):
CUI Fei LUO Rong-cheng CHEN Jin-zhang CHEN Bin HUANG Yu-xian
Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
关键词:
乳腺癌肿瘤标志物Herceptin生物化疗Her-2/neu紫杉醇表阿霉素
Keywords:
breast cancertumor markersHerceptinbiochemotherapyHer-2/neuepirubicinTAX
分类号:
R737.9;R979.1
摘要:
目的 比较Herceptin联合紫杉醇(TAX)的生物化疗组和表阿霉素(EPI)联合TAX单纯化疗组治疗Her-2/neu阳性表达的乳腺癌患者的疗效评估以及前者血清肿瘤标志物的变化及意义。方法 选择免疫组化法检查Her-2/neu为阳性的乳腺癌患者为入选对象,以32例接受Herceptin联合TAX方案治疗者为研究组,41例接受EPI联合TAX方案治疗者为对照组,分别观察上述两组病人的疗效、研究组病人Her-2/neu表达强度与疗效之间的关系及该组患者血清肿瘤标志物的变化。结果 Herceptin联合TAX治疗乳腺癌的客观有效率(RR%)、临床受益率(RR+SD%)均明显高于EPI联合TAX组;生物化疗组中,免疫组化检测结果为Her-2/neu(+)、Her-2/neu(++)、Her-2/neu(+++)的患者的临床有效率分别为0%、44.4%和63.6%;单纯化疗组分别为8.3%、36.4%和38.9%;Herceptin联合TAX方案化疗后,血清肿瘤标志物水平与化疗前比较有不同程度降低,CA153、TPS及CEA与治疗前相比有显著性差异(P<0.05),而CA125则无显著性差异(P>0.05)。结论 对于Her-2/neu阳性的晚期乳腺癌患者,Herceptin联合TAX方案组的疗效明显优于TAX联合EPI方案组,对Her-2/neu(+++)的乳腺癌患者,Herceptin联合TAX治疗的有效率高于Her-2/neu(++)的患者。肿瘤标志物CEA、TPS、CA153在判定疗效上也有一定的临床价值。
Abstract:
Objective To compare the therapeutic effects of biochemotherapy regimen with Herceptin plus taxol (TAX) and the chemotherapy regimen with epirubicin plus TAX against Her-2/neu-positive breast cancer and observe the changes in serum tumor markers in patients receiving biochemotherapy. Methods Seventy-three patients with advanced breast cancer positive for Her-2/neu as revealed by immunohistochemistry were divided into the study group (n=32) to receive treatment with the regimen of Herceptin plus TAX and control group (n=41) with the regimen of epirubicin(EPI) plus TAX. The therapeutic effects of the regimens were observed and in the study group, the relationship of the therapeutic effect with Her-2/neu positivity and changes in serum tumor markers were examined. Results The objective response rate and clinical benefit response rate were obviously higher in the study group than in the control group. In the study group, the clinical response rate of patients with positive immunostaining for Her-2/neu of grades 1+, 2+ and 3+ were 0%, 44.4% and 63.6%, respectively, as compared with those in the control group of 8.3%, 36.4%, and 38.9%, respectively, and the treatment resulted in lowered levels of serum tumor markers without significant changes in CA153, tps and CEA (P<0.05) after treatment, but CA125 showed no significant difference (P>0.05). Conclusions In patients with advanced breast cancer with positive immunostaining for Her-2/neu of grade 3+, the regimen of Herceptin plus TAX can be more effective than the chemotherapeutic regimen of EPI plus TAX. Patients with Her-2/neu (+++) benefit more from the treatment than those with Her-2/neu (++). Serum CEA, CA153 and TPS levels also possess some value in evaluating the therapeutic effects of the regimens.

参考文献/References:

[1] 周爱萍.乳腺癌靶向治疗:Herceptin的研究进展[J].国外医学·肿瘤学分册,2000,8(4):167-70.
[2] Baselga J,Tripathy D,Mendelsohn J,et al.Phase Ⅱ study of weekly intravenous trastuzumab (Herceptin) in patients with HER-2/neu overexpressing metastatic breast cancer[J].J Clin Oncol,1996,14(3):737-44.
[3] Vogel CL,Cobleigh MA,Tripathy D,et al.First-line Herceptin mo notherapy in metastatic breast cancer [J].Oncology,2001,61 (Suppl2):37-42.
[4] 宋海珠,罗荣城.Herceptin治疗转移性乳腺癌的研究进展[J].中国肿瘤生物治疗杂志,2002,9(2):144-5.Song HZ,Luo RC.Progress of the therapy of matestatic breast cancer ofherceptin[J].Chin J Cancer Biother,2002,9(2):144-5.
[5] Fornier M,Esteva FJ,Seidman AD.Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer [J].Semin Oncol,2000,27(6 Suppl 11):38-45.
[6] 孙燕,周际昌.临床肿瘤内科手册[M].第4版,北京:人民卫生出版社,2003.107-13.
[7] Hayes DF,Thor AD.c-erbB-2 in breast cancer:Development of a clinically useful marker[J].Semin Oncol,2002,29(3):231-45.
[8] Aziz A,Pervez S,Khan S,et al.Significance ofimmunohistohemical c-erbB-2 product localization pattern for prognosis in human breast cancer[J].Pathol Oncol Res,2001,7(3):190-6.
[9] Baselga J,Norton L,Albanell J,et al.Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J].Cancer Res,1998,58(13):2825-31.
[10] Senapad S,Neungton S,Thirapakawong C,et al.Predictive value of the combined serum CA125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer [J].Anticancer Res,2000,20(2B):1297-300.
[11] 汤沼猷.现代肿瘤学[M].上海医科大学出版社,1993.3549.
[12] Berruti A,Tampellini M,Torta M,et al.Prognostic value in predicting overall survival of two mucinus markers:CA15-3 and CA125in breast cancer patients at first relapse of disease [J].Eur J Cancer,1994,30A(14):2082-4.
[13] Krammer S,RaffU,Jager W,et al.CA125 as an indicator ofpleural metastases in breast cancer[J].Anticancer Res,1996,16(5B):3165-8.
[14] Arjun MD,Thomas MD,Steven PD.Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women[J].Cancer,1999,85(9):2068-72.

相似文献/References:

[1]黄伟斌,姚广裕,刘民锋,等.心肌钙蛋白I 对蒽环类化疗的乳腺癌患者心脏毒性的预测价值[J].南方医科大学学报,2011,(06):1047.
[2]郭启帅,黄曦,李少林.沉默PeroxiredoxinⅠ基因对乳腺癌裸鼠移植瘤放射敏感性的影响[J].南方医科大学学报,2011,(07):1119.
[3]冯云,周会行,李军红,等.肝癌缺失基因1和磷酸化粘着斑激酶蛋白在乳腺癌组织中的表达及意义[J].南方医科大学学报,2011,(08):1448.
[4]夏青,史艳侠,刘东耕,等.一项单中心的25例男性乳腺癌临床病理特点总结[J].南方医科大学学报,2011,(09):1469.
[5]李嗣杰,贾泓瑶,吴迪,等.肿瘤翻译调控蛋白在人乳腺癌组织中的表达及临床意义[J].南方医科大学学报,2011,(09):1560.
[6]马吉光,王宁菊,于文洁.“三阴”型与非“三阴”型乳腺癌患者的生物学行为差异性分析[J].南方医科大学学报,2011,(10):1729.
[7]王玲,单保恩,桑梅香,等.靶向沉默p65 基因对人乳腺癌细胞MDA-MB-231增殖及凋亡的影响[J].南方医科大学学报,2011,(10):1742.
[8]陈可和,梁博,邹镇洪,等.Rheb和Rheb’D60K突变基因重组慢病毒载体的构建、鉴定及其对肝癌细胞凋亡的影响[J].南方医科大学学报,2012,(03):341.
[9]胡孝渠,秦利,苏逢锡,等.载体介导HER-2RNA干扰治疗乳腺癌研究[J].南方医科大学学报,2006,(05):570.
 HU Xiao-qu,QIN Li,SU Feng-xi,et al.Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer[J].Journal of Southern Medical University,2006,(12):570.
[10]王晓冰,杨清绪,裴小娟,等.乳腺浸润性癌血管生成相关因子的表达及其临床意义[J].南方医科大学学报,2006,(06):860.
 WANG Xiao-bing,YANG Qing-xu,PEI Xiao-juan Department of Pathology,et al.Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance[J].Journal of Southern Medical University,2006,(12):860.

备注/Memo

备注/Memo:
收稿日期:2005-2-11。
作者简介:崔斐(1981- ),在读硕士,电话:020-62842113,E-mail:cuif519@yahoo.com.cn.
更新日期/Last Update: 1900-01-01